A protocol for the diagnosis and treatment of metabolic osteopathy in patients with home-based parenteral nutrition;Protocolo para el diagnóstico y tratamiento de la osteopatía metabólica en el enfermo con nutrición parenteral domiciliaria

Nutricion Hospitalaria

Volumn 22, Issue 3, 2007, Pages 351-357

  Gomez Enterria P ^a   Laborda Gonzalez L ^b   Martínez Faedo, Ceferino ^a,c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HUCA   (Spain)

Author keywords

Home based parenteral nutrition; Osteoporosis

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; DISEASE SEVERITY; EARLY DIAGNOSIS; ENTEROPATHY; FRAGILITY FRACTURE; HOME CARE; HUMAN; METABOLIC BONE DISEASE; OSTEOPOROSIS; PARENTERAL NUTRITION; QUALITY OF LIFE; TREATMENT OUTCOME;

ALGORITHMS; BONE DISEASES, METABOLIC; CLINICAL PROTOCOLS; HUMANS; PARENTERAL NUTRITION, HOME;

EID: 34250006574     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Buchman AL, Moukarzal A: Metabolic bone disease associated with total parenteral nutrition. Clin Nutr 2000; 19(4):217-31.
2. Seidner Dl, Licata A: Parenteral nutrition-associated metabolic bone disease: pathophisiology, evaluation and treatment. N C P 2000; 15:163-70 .
3. WHO. Assessment of osteoporotic fracture risk and its role in screening for postmenopausal osteoporosis. WHO Technical Report Series 843, 1994.
4. Leslie WD, Adler RA, El-Hajj Fuleihan G y cols.: Application of the 1994 WHO classification to populations other than postmenopausal caucasian women: the ISCD Official Positions. J Clin Densitom 2006; 9(1):22-30.
5. Haderslev KV, Tjellesen L, Halderslev PH y cols.: Assessment of the longitudinal changes in bone mineral density in patients receiving home parenteral nutrition. JPEN 2004; 28:289-9415.
6. Cohen-Solal M, Baudoin C, Joly F, Vahed K, Daoust L, Vernejoul MC, Messing B: Osteoporosis in patients on long-term home parenteral nutrition: a longitudinal study. J Bone Miner Res 2003; 18:1989-94.
7. Pironi L, Morselli Labate A, Pertkiewiwicz M y cols.: Prevalence of bone disease in patients on home parenteral nutrition. Clin Nutr 2002; 21:289-96.
8. Pironi L, Tjellesen L, Francesco A y cols.: Bone mineral density in patients on home parenteral nutrition: a follow-up study. Clin Nutr 2004; 23:1288-302.
9. Shaker J, Lukert B: Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin N Am 2005; 34:341-53.
10. Wood RJ, Bengoa JM, Sitrin MD, Rosemberg IM: Calciuretic effect of cyclic versus continous total parenteral nutrition. Am J Clin Nutr 1985; 41:614-913.
11. Charney P: ASPEN Statement on aluminium parenteral nutrition solutions. NCP 2004; 19:416-7.
12. Advenier E, Landry C, Colomb V y cols.: Aluminium contamination of parenteral nutrition and aluminium loading in children on long-term parenteral nutrition. Journal of Pediatrics Gastroenterology and Nutrition 2003; 36:448-53.
13. Gura KM, Puder M: Recent developments in aluminiun contamination of products used in parenteral nutrition. Cur Opin Clin Nut Metab Care 2006; 9:239-46.
14. Seligman JV, Basi SS, Deitel M, Bayley TA, Khanna RK: Metabolic bone disease in a patient on long term total parenteral nutrition: a case report with review of the literature. JPEN 1984; 8:722-7.
15. Guañabens N: Osteoporosis 2003. Med Clin (Barc) 2003; 121:625-30.
16. Orozco P: Actualización en el abordaje y tratamiento de la osteoporosis. Información Terapéutica del Sistema Nacional de Salud 2001; 25(5):117-141.http://www.msc.es/estadEstudios/publicaciones/docs/ osteoporosis25_5.pdf.
17. Rossow JE, Anderson GL, Prentice RL y cols.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Iniciative randomized controlled trial. JAMA 2002; 288;321-33.
18. Sosa M, Hernández D: Tratamiento de la osteoporosis. Medicine 2006; 9(60):3880-4 .
19. Roig Escofet D: Tratamiento de la osteoporosis. Del empirismo a la evidencia. Rev Esp Reumatol 2004; 31(1):1-5.
20. Epstein S: Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006; 28 (2):151-73 .
21. McCluge MR: Biphosphonates. Endocrinol Metab Clin N Am 2003; 32:253-71.
22. Díaz Curiel M, Santana Zapatero H: Bifosfonatos. Medicine 2002; 84(8):4529-34.
23. Hernández JL, Riancho JA, González Macías J: Bifosfonatos intravenosos. Med Clin (Bar) 2005; 124(9):348-54.
24. Miller RG, Chretien KC, Leoni LA y cols.: Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates. J Clin Rheumatol 2005 Feb; 11 (1):2-7.
25. Delmas PD, Adamis S, Strugala C: Intravenous ibandronate injections in postmenopausal women with osteoporosis: one year results from the dosing intravenous administration study. Arthritis Rheum 2006 Jun; 54(6):1838-46 .
26. Reginster JY: Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Curr Pharm Des 2005; 11(28):3711-28.
27. Reid IR, Brown JP, Burckhart P, Horowitz Z: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346(9):653-61.
28. Hadersley KV, Tjellesen L, Sorensen HD, Staun M: Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition. Am J Clin Nutr 2002; 76:482-812.
29. Grady D, Herrington D, Bittner V y cols.: Cardiovascular disease outcome during 6,8 years of hormone therapy. JAMA 2002; 288:49-57.
30. González Macías J: Tratamiento de la osteoporosis con PTH. En: Manual práctico de osteoporosis y enfermedades del metabolismo mineral. Jarpyo Editores 2004; 211-218.
31. Rubin MR, Bilezikian JF: New anabolic therapies in osteoporosis. Endocrinol Metab Clin N Am 2003; 32:285-307.
32. Geusens P, Reid D: Newer drug treatments: Their effects on fracture prevention. Best Practice & Research Clinical Rheumatology 2005; 19(6)983-9.
33. Meunier P, Roux C, Seeman E y cols.: The effect of strontium ranelate on the risk of vertebral fractures in women with postmenopausal osteoporosis. N Engl J Med 2004; 350:459-68.
34. Reginster JY, Seeman E, Veinejoul MC y cols.: Strontium ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis: TROPOS Study. J Clin Endocrinol Metab 2005; 90(5):2816-22.
35. O'Donnel S, Craney A, Wells GA, Adachi JD, Reginster JY: Strontium ranelate for preventing and treating postmenopausal osteoporosis. The Cochrabe Datebase of Syst Rev 2006; Oct 18;(4):CD 005326.
36. McClung MR, Lewiecki EM, Cohen SB y cols.: Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821-31.
37. Torrijos A: Terapia combinada de la osteoporosis. Rev Esp Reumatol 2004; 3(1):24-30.
38. Emkey RD, Ettinger M: Improving Compliance and persistence with biphosphonate therapy for osteoporosis. Am J Med 2006; 119(4 Supl):S18-24.